drugset / Trial / NCT02260180

Study of A-101 for the Treatment of Seborrheic Keratosis

NCT02260180

Phase 2 Completed 119 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.

Timeline

Start
2014-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrogen Peroxide Small molecule 32.5 % Topical
Comparator Hydrogen Peroxide Small molecule 40 % Topical

Indications